NGF and osteoarthritis: Previously, the reduction of pain markers with a combination of senolytic drugs has been observed in an in vivo osteoarthritis model, where they observed a decrease in NGF, calcitonin gene-related peptide (CGRP) and selectively removed senescent cells [33], further supporting our findings.